The trademark application vicore pharma was filed by Vicore Pharma AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on August 15, 2021, and it was registered by office on November 22, 2021 without any oppositions.
The application was filed in Swedish (English was selected as the second language).
Change of name and professional address of the trademark registration was recorded on December 12, 2021. Change of name and professional address of the trademark registration was recorded on February 15, 2023.
Goods And Services
The mark was filed in class 5 with Pharmaceuticals and medical preparations for human use, namely, prescription drugs, namely, pills, tablets, capsules, caplets, and liquid drops sachets for the treatment of fibrotic lung disease.
The mark was filed in class 42 with following description of goods:
Medical and pharmacological research services
Medical and pharmacological research services within the fields of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases
Medical and pharmacological research services within the fields of pulmonary fibrosis, namely IPF, pulmonary sarcoidosis and diffuse systemic sclerosis (lung manifestations)
Pharmaceutical research and development
Scientific research and development
Medical research laboratory services
Medical research
Providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Pharmaceutical drug development services
Pharmaceutical drug delivery system development services
Pharmaceutical drug development services, namely, preparation and/or formulation of pharmaceuticals
Medical product testing services
Clinical research and professional expertise relating thereto in the nature of professional expertise in the field of clinical research for others
All of the foregoing services for the treatment of fibrotic lung disease.